Patent: 8,461,101
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,461,101
Title: | Targeting PAX2 for the treatment of breast cancer |
Abstract: | The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. |
Inventor(s): | Donald; Carlton D. (Mount Pleasant, SC) |
Assignee: | Phigenix, Inc. (Atlanata, GA) |
Application Number: | 13/114,824 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,461,101 |
Patent Claims: | see list of patent claims |
Details for Patent 8,461,101
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2025-10-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2025-10-14 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2025-10-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |